|Synonyms||vitamin D3, activated 7-dehydrocholesterol|
|AHFS/Drugs.com||Professional Drug Facts|
|By mouth, intramuscular injection|
|Chemical and physical data|
|Molar mass||384.64 g/mol|
|3D model (JSmol)|
|Melting point||83 to 86 °C (181 to 187 °F)|
|Boiling point||496.4 °C (925.5 °F)|
|Solubility in water||Practically insoluble in water, freely soluble in ethanol, methanol and some other organic solvents. Slightly soluble in vegetable oils. mg/mL (20 °C)|
Cholecalciferol, also known as vitamin D3 and colecalciferol, is a type of vitamin D which is made by the skin, found in some foods, and taken as a dietary supplement. It is used to treat and prevent vitamin D deficiency and associated diseases, including rickets. It is also used for familial hypophosphatemia, hypoparathyroidism that is causing low blood calcium, and Fanconi syndrome. It is usually taken by mouth.
Excessive doses can result in vomiting, constipation, weakness, and confusion. Other risks include kidney stones. Normal doses are safe in pregnancy. It may not be effective in people with severe kidney disease.
Cholecalciferol is made in the skin following UVB light exposure. It is converted in the liver to calcifediol (25-hydroxyvitamin D) which is then converted in the kidney to calcitriol (1,25-dihydroxyvitamin D). One of its actions is to increase the uptake of calcium by the intestines. It is found in food such as some fish, cheese, and eggs. Certain foods such as milk have cholecalciferol added to them in some countries.
Cholecalciferol was first described in 1936. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Cholecalciferol is available as a generic medication and over the counter.
Vitamin D deficiency
Cholecalciferol is a form of vitamin D which is naturally synthesized in skin and functions as a pro-hormone, being converted to calcitriol. This is important for maintaining calcium levels and promoting bone health and development. As a medication, cholecalciferol may be taken as a dietary supplement to prevent or to treat vitamin D deficiency. One gram is 40,000,000 (40x106) IU, equivalently 1 IU is 0.025 µg. Dietary reference intake values for vitamin D (cholecalciferol and/or ergocalciferol) have been established and recommendations vary depending on the country:
- In the US: 15 µg/d (600 IU per day) for all individuals (males, female, pregnant/lactating women) between the ages of 1 and 70 years old, inclusive. For all individuals older than 70 years, 20 µg/d (800 IU per day) is recommended.
- In the EU: 20 µg/d (800 IU per day)
- In France: 25 µg/d (1000 IU per day)
Many question whether the current recommended intake is sufficient to meet physiological needs. Individuals without regular sun exposure, the obese, and darker skinned individuals all have lower blood levels and require more supplementation.
The Institute of Medicine in 2010 recommended a maximum uptake of vitamin D of 4,000 IU/day, finding that the dose for lowest observed adverse effect level is 40,000 IU daily for at least 12 weeks, and that there was a single case of toxicity above 10,000 IU after more than 7 years of daily intake; this case of toxicity occurred in circumstances that have led other researchers to dispute it as a credible case to consider when making vitamin D intake recommendations. Patients with severe vitamin D deficiency will require treatment with a loading dose; its magnitude can be calculated based on the actual serum 25-hydroxy-vitamin D level and body weight.
There are conflicting reports concerning the relative effectiveness of cholecalciferol (D3) versus ergocalciferol (D2), with some studies suggesting less efficacy of D2, and others showing no difference. There are differences in absorption, binding and inactivation of the two forms, with evidence usually favoring cholecalciferol in raising levels in blood, although more research is needed.
A much less common use of cholecalciferol therapy in rickets utilizes a single large dose and has been called stoss therapy. Treatment is given either orally or by intramuscular injection of 300,000 IU (7,500 µg) to 500,000 IU (12,500 µg = 12.5 mg), in a single dose, or sometimes in two to four divided doses. There are concerns about the safety of such large doses.
A meta-analysis of 2007 concluded that daily intake of 1000 to 2000 IU per day of vitamin D3 could reduce the incidence of colorectal cancer with minimal risk. Also a 2008 study published in Cancer Research has shown the addition of vitamin D3 (along with calcium) to the diet of some mice fed a regimen similar in nutritional content to a new Western diet with 1000 IU cholecalciferol per day prevented colon cancer development. In humans, with 400 IU daily, there was no effect of cholecalciferol supplements on the risk of colorectal cancer.
Supplements are not recommended for prevention of cancer as any effects of cholecalciferol are very small. Although correlations exist between low levels of blood serum cholecalciferol and higher rates of various cancers, multiple sclerosis, tuberculosis, heart disease, and diabetes, the consensus is that supplementing levels is not beneficial. It is thought that tuberculosis may result in lower levels. It, however, is not entirely clear how the two are related.
Mechanism of action
By itself cholecalciferol is inactive. It is converted to its active form by two hydroxylations: the first in the liver, by CYP2R1 or CYP27A1, to form 25-hydroxycholecalciferol (calcifediol, 25-OH vitamin D3). The second hydroxylation occurs mainly in the kidney through the action of CYP27B1 to convert 25-OH vitamin D3 into 1,25-dihydroxycholecalciferol (calcitriol, 1,25-(OH)2vitamin D3). All these metabolites are bound in blood to the vitamin D-binding protein. The action of calcitriol is mediated by the vitamin D receptor, a nuclear receptor which regulates the synthesis of hundreds of proteins and is present in virtually every cell in the body.
Click on icon in lower right corner to open. Click on genes, proteins and metabolites below to link to respective articles. [§ 1]
7-Dehydrocholesterol is the precursor of cholecalciferol. Within the epidermal layer of skin, 7-Dehydrocholesterol undergoes an electrocyclic reaction as a result of UVB light at wavelengths between 290 and 315 nm, with peak synthesis occurring between 295 and 300 nm. This results in the opening of the vitamin precursor B-ring through a conrotatory pathway making previtamin D3 (pre-cholecalciferol). In a process which is independent of UV light, the pre-cholecalciferol then undergoes a [1,7] antarafacial sigmatropic rearrangement  and therein finally isomerizes to form vitamin D3.
The active UVB wavelengths are present in sunlight, and sufficient amounts of cholecalciferol can be produced with moderate exposure of the skin, depending on the strength of the sun. Time of day, season, and altitude affect the strength of the sun, and pollution, cloud cover or glass all reduce the amount of UVB exposure. Exposure of face, arms and legs, averaging 5–30 minutes twice per week, may be sufficient, but the darker the skin, and the weaker the sunlight, the more minutes of exposure are needed. Vitamin D overdose is impossible from UV exposure; the skin reaches an equilibrium where the vitamin degrades as fast as it is created.
Cholecalciferol can be produced in skin from the light emitted by the UV lamps in tanning beds, which produce ultraviolet primarily in the UVA spectrum, but typically produce 4% to 10% of the total UV emissions as UVB. Levels in blood are higher in frequent uses of tanning salons.
Whether cholecalciferol and all forms of vitamin D are by definition "vitamins" can be disputed, since the definition of vitamins includes that the substance cannot be synthesized by the body and must be ingested. Cholecalciferol is synthesized by the body during UVB radiation exposure.
The three steps in the synthesis and activation of vitamin D3 are regulated as follows:
- Cholecalciferol is synthesized in the skin from 7-dehydrocholesterol under the action of ultraviolet B (UVB) light. It reaches an equilibrium after several minutes depending on the intensity of the UVB in the sunlight - determined by latitude, season, cloud cover, and altitude - and the age and degree of pigmentation of the skin.
- Hydroxylation in the endoplasmic reticulum of liver hepatocytes of cholecalciferol to calcifediol (25-hydroxycholecalciferol) by 25-hydroxylase is loosely regulated, if at all, and blood levels of this molecule largely reflect the amount of cholecalciferol produced in the skin combined with any vitamin D2 or D3 ingested.
- Hydroxylation in the kidneys of calcifediol to calcitriol by 1-alpha-hydroxylase is tightly regulated: it is stimulated by parathyroid hormone and serves as the major control point in the production of the active circulating hormone calcitriol (1,25-dihydroxyvitamin D3).
Cholecalciferol is produced industrially for use in vitamin supplements and to fortify foods. As a pharmaceutical drug it is called cholecalciferol (USAN) or colecalciferol (INN, BAN). It is produced by the ultraviolet irradiation of 7-dehydrocholesterol extracted from lanolin found in sheep's wool. Cholesterol is extracted from wool grease and wool wax alcohols obtained from the cleaning of wool after shearing. The cholesterol undergoes a four-step process to make 7-dehydrocholesterol, the same compound that is produced in the skin of animals. The 7-dehydrocholesterol is then irradiated with ultraviolet light. Some unwanted isomers are formed during irradiation: these are removed by various techniques, leaving a resin which melts at about room temperature and usually has a potency of 25,000,000 to 30,000,000 International Units per gram.
Use as rodenticide
Rodents are somewhat more susceptible to high doses than other species, and cholecalciferol has been used in poison bait for the control of these pests. It has been claimed that the compound is less toxic to non-target species. However, in practice it has been found that use of cholecalciferol in rodenticides represents a significant hazard to other animals, such as dogs and cats. "Cholecalciferol produces hypercalcemia, which results in systemic calcification of soft tissue, leading to renal failure, cardiac abnormalities, hypertension, CNS depression, and GI upset. Signs generally develop within 18-36 hr of ingestion and can include depression, anorexia, polyuria, and polydipsia."
In New Zealand, possums have become a significant pest animal, and cholecalciferol has been used as the active ingredient in lethal gel baits and cereal pellet baits "DECAL" for possum control. The LD50 is 16.8 mg/kg, but only 9.8 mg/kg if calcium carbonate is added to the bait. Kidneys and heart are target organs.
The wholesale cost in the Costa Rica is about 2.15 USD per 30 ml bottle of 10,000 IU/ml. In the United States treatment costs less than 25 USD per month. In the UK, the cost for a month's treatment to the NHS can be less than 3 GBP.
- Hypervitaminosis D, Vitamin D poisoning
- Ergocalciferol, vitamin D2.
- 25-Hydroxyvitamin D3 1-alpha-Hydroxylase, a kidney enzyme that converts calcifediol to calcitriol.
- Coulston, Ann M.; Boushey, Carol; Ferruzzi, Mario (2013). Nutrition in the Prevention and Treatment of Disease. Academic Press. p. 818. ISBN 9780123918840. Archived from the original on 2016-12-30.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 703–704. ISBN 9780857111562.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 496. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 231. ISBN 9781284057560.
- "Cholecalciferol (Professional Patient Advice) - Drugs.com". www.drugs.com. Archived from the original on 30 December 2016. Retrieved 29 December 2016.
- "Aviticol 1 000 IU Capsules - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 30 December 2016. Retrieved 29 December 2016.
- Norman, AW (August 2008). "From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health". The American Journal of Clinical Nutrition. 88 (2): 491S–499S. PMID 18689389.
- "Office of Dietary Supplements - Vitamin D". ods.od.nih.gov. 11 February 2016. Archived from the original on 31 December 2016. Retrieved 30 December 2016.
- Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 451. ISBN 9783527607495. Archived from the original on 2016-12-30.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- DRIs for Calcium and Vitamin D Archived 2010-12-24 at the Wayback Machine.
- Vieth R (May 1999). "Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety". Am. J. Clin. Nutr. 69 (5): 842–56. PMID 10232622.
- van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H (April 2010). "Cholecalciferol loading dose guideline for vitamin D-deficient adults". Eur. J. Endocrinol. 162 (4): 805–11. doi:10.1530/EJE-09-0932. PMID 20139241.
- Tripkovic, L; Lambert, H; Hart, K; Smith, CP; Bucca, G; Penson, S; Chope, G; Hyppönen, E; Berry, J; Vieth, R; Lanham-New, S (June 2012). "Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis". The American Journal of Clinical Nutrition. 95 (6): 1357–64. doi:10.3945/ajcn.111.031070. PMC 3349454. PMID 22552031.
- Shah BR, Finberg L (September 1994). "Single-day therapy for nutritional vitamin D-deficiency rickets: a preferred method". J. Pediatr. 125 (3): 487–90. doi:10.1016/S0022-3476(05)83303-7. PMID 8071764.
- Chatterjee, D; Swamy, MK; Gupta, V; Sharma, V; Sharma, A; Chatterjee, K (1 March 2017). "Safety and Efficacy of Stosstherapy in Nutritional Rickets". Journal of Clinical Research in Pediatric Endocrinology. 9 (1): 63–69. doi:10.4274/jcrpe.3557. PMC 5363167. PMID 27550890.
- Bothra, M; Gupta, N; Jain, V (1 June 2016). "Effect of intramuscular cholecalciferol megadose in children with nutritional rickets". Journal of Pediatric Endocrinology & Metabolism. 29 (6): 687–92. doi:10.1515/jpem-2015-0031. PMID 26913455.
- Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF (2007). "Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis". American Journal of Preventive Medicine (Meta-Analysis). 32 (3): 210–6. doi:10.1016/j.amepre.2006.11.004. PMID 17296473.
- Yang K, Kurihara N, Fan K, Newmark H, Rigas B, Bancroft L, Corner G, Livote E, Lesser M, Edelmann W, Velcich A, Lipkin M, Augenlicht L (October 2008). "Dietary induction of colonic tumors in a mouse model of sporadic colon cancer". Cancer Res. 68 (19): 7803–10. doi:10.1158/0008-5472.CAN-08-1209. PMID 18829535.
- Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L, Prentice RL, Robbins J, Rohan TE, Sarto GE, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE (February 2006). "Calcium plus vitamin D supplementation and the risk of colorectal cancer". N. Engl. J. Med. 354 (7): 684–96. doi:10.1056/NEJMoa055222. PMID 16481636.
- Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C (January 10, 2014). "Vitamin D supplementation for prevention of mortality in adults". The Cochrane Database of Systematic Reviews. 1: CD007470. doi:10.1002/14651858.cd007470.pub3. PMID 24414552.
- Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF (February 2006). "The Role of Vitamin D in Cancer Prevention". Am J Public Health. 96 (2): 252–261. doi:10.2105/AJPH.2004.045260. PMC 1470481. PMID 16380576.
- Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (January 2011). "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know". J. Clin. Endocrinol. Metab. 96 (1): 53–8. doi:10.1210/jc.2010-2704. PMC 3046611. PMID 21118827.
- Gou, X; Pan, L; Tang, F; Gao, H; Xiao, D (August 2018). "The association between vitamin D status and tuberculosis in children: A meta-analysis". Medicine. 97 (35): e12179. doi:10.1097/MD.0000000000012179. PMID 30170465.
- Keflie, TS; Nölle, N; Lambert, C; Nohr, D; Biesalski, HK (October 2015). "Vitamin D deficiencies among tuberculosis patients in Africa: A systematic review". Nutrition (Burbank, Los Angeles County, Calif.). 31 (10): 1204–12. doi:10.1016/j.nut.2015.05.003. PMID 26333888.
- "cholecalciferol" at Dorland's Medical Dictionary
- "About Vitamin D". University of California, Riverside. November 2011. Archived from the original on October 16, 2017. Retrieved October 15, 2017.
- Wacker, M; Holick, MF (1 January 2013). "Sunlight and Vitamin D: A global perspective for health. (Review)". Dermato-endocrinology. 5 (1): 51–108. doi:10.4161/derm.24494. PMC 3897598. PMID 24494042.
- MacLaughlin, JA; Anderson, RR; Holick, MF (28 May 1982). "Spectral character of sunlight modulates photosynthesis of previtamin D3 and its photoisomers in human skin". Science. 216 (4549): 1001–3. doi:10.1126/science.6281884. PMID 6281884.
- Okamura, W. H.; Elnagar, H. Y.; Ruther, M. & S. Dobreff. (1993). "Thermal [1,7]-sigmatropic shift of previtamin D3 to vitamin D3: synthesis and study of pentadeuterio derivatives". Journal of Organic Chemistry. 58 (3): 600–610. doi:10.1021/jo00055a011.
- Vitamin D3 Story. Archived 2012-01-22 at the Wayback Machine. Retrieved 8 April 2012.
- "Vitashine Vegan Vitamin D3 Supplements". Archived from the original on 2013-03-04. Retrieved 2013-03-15.
- Ting Wang; Göran Bengtsson; Ingvar Kärnefelt; Lars Olof Björn (Sep 1, 2001). "Provitamins and vitamins D₂ and D₃ in Cladina spp. over a latitudinal gradient: possible correlation with UV levels". J Photochem Photobiol B. Department of Plant physiology, Lund University, Sweden. 62 (1–2): 118–22. doi:10.1016/s1011-1344(01)00160-9. PMID 11693362. Archived from the original on 2012-10-28. Retrieved 2013-03-15.
- "Merck Veterinary Manual - Rodenticide Poisoning: Introduction". Archived from the original on 2007-01-17.
- Morgan D (2006). "Field efficacy of cholecalciferol gel baits for possum (Trichosurus vulpecula) control". New Zealand Journal of Zoology. 33 (3): 221–8. doi:10.1080/03014223.2006.9518449.
- Jolly SE, Henderson RJ, Frampton C, Eason CT (1995). "Cholecalciferol Toxicity and Its Enhancement by Calcium Carbonate in the Common Brushtail Possum". Wildlife Research. 22 (5): 579–83. doi:10.1071/WR9950579.
- "Kiwicare Material Safety Data Sheet" (PDF). Archived from the original (PDF) on 2013-02-10.
- "Single Drug Information | International Medical Products Price Guide". mshpriceguide.org. Archived from the original on 10 August 2017. Retrieved 6 July 2017.
- NICE. "Colecalciferol". Retrieved 3 May 2018.